Abstract
Human papillomavirus (HPV), particularly strains 16 and 18, is the most oncogenic subset of the virus family, responsible for the majority of cervical cancers worldwide. Despite its ubiquity, the natural history of HPV infection demonstrates that the immune system is the decisive actor in clearance, with more than 95% of infections (including HPV‑16 And HPV‑18) resolving spontaneously within one to two years. Vaccination programs are often credited with reducing cervical cancer incidence, but vaccines do not prevent infections in the strict biological sense. Instead, they function as strain‑specific alarms, directing the immune system toward recognition of certain viral proteins. Clearance remains immune‑driven, persistence is rare, and progression to cancer is a long process dependent on immune strength. This article expands upon The HPV Vaccines Biological Impossibilities (HVBI) Theory of Praveen Dalal, situating vaccines as signals rather than shields, and integrates discussions from recent analyses on discrediting of screening and treatment, immune system dynamics, and vaccine impossibilities. The aim is to provoke a scientific debate about credit assignment, risk communication, and the philosophy of preventive medicine.
Introduction
HPV infection is among the most common viral exposures in humans, transmitted through sexual contact and often encountered early in reproductive life. Despite its prevalence, the majority of infections are transient, cleared by the immune system without clinical consequence. Only a small minority of persistent infections progress to cervical intraepithelial neoplasia (CIN) and, ultimately, invasive cancer. Strains HPV‑16 and HPV‑18 are particularly oncogenic, accounting for approximately 70% of cervical cancers worldwide.
Vaccination against these strains has been heralded as a breakthrough in cancer prevention, yet the biological mechanics of clearance remain unchanged: the immune system clears infections, while vaccines merely accelerate recognition of only those viral proteins that are covered by such vaccines. This distinction—between clearance and signal—is often blurred in public health messaging, leading to an inflated perception of vaccine efficacy.
This article is part of the series on the HPV Vaccines Biological Impossibilities (HVBI) Theory by Praveen Dalal. We have already covered the Screening and Treatment Aspect and the Immune System Dynamics in HPV Infections and Vaccinations. This is the third in the series, expanding the discussion with deeper analysis of vaccine impossibilities, the discrediting of screening programs, and population-level outcomes.
Methods
This article synthesizes epidemiological data, immunological studies, and theoretical frameworks from the HVBI Theory. It integrates discussions from three key analyses:
(1) The HPV Vaccines Biological Impossibilities (HVBI) Theory
(2) The Deliberate Discrediting Of HPV Screening And Treatment By Vaccine Lobby Post‑2006
(3) HPV‑16 And HPV‑18: Immune System Dynamics, Vaccination, And Population-Level Outcomes
The framework emphasizes the immune system’s centrality, positioning vaccines as alarm systems rather than preventive shields, and situates these findings within broader public health narratives.
Results
Natural clearance of HPV‑16 and HPV‑18 occurs in more than 95% of individuals with normal immune function within one to two years. Persistence is rare, requiring decades to progress to CIN3 and invasive cancer. Immunocompromised individuals show accelerated persistence, with CIN3 appearing within five years and invasive cancer within a decade. Vaccines induce antibodies but do not clear infections. Their role is limited to raising alarms against covered strains, with no effect on clearance timelines.
| Aspect | Natural Clearance (HPV‑16/18) | Vaccination Impact (HPV‑16/18) |
|---|---|---|
| Clearance mechanism | Immune system clears >90% within 1–2 years | Vaccines do not clear infections |
| Persistence outcome | ~5–10% persist, risk of CIN3 decades later | Makes infections that may become persistence visible to immune system. But the outcome follows in any case |
| Strain coverage | All strains eventually cleared | Only covered strains (16/18, sometimes 31/33/45 in newer vaccines) |
| Immunocompromised groups | Accelerated persistence, CIN3 within 5 years | Limited benefit; screening essential |
| Reinfection | Slow identification due to non-extensive natural memory. But eventually able to ward off the infection, if capable. | Immediate identification of reinfection for covered strains |
| Attribution in messaging | Clearance credited to immune system | HPV infection alarm system for strains covered by vaccine |
Explanation: Natural clearance is universal and immune-driven, while vaccination is strain-specific and functions as an alarm system. HPV vaccines expose the virus early but do not alter clearance itself.
Dedicated Discussions
(1) The HPV Vaccines Biological Impossibilities (HVBI) Theory
The HVBI Theory Of Praveen Dalal has scientifically established that HPV vaccines are biologically incapable of preventing infections. They cannot alter the natural history of HPV clearance, which is immune-driven. Instead, vaccines act as strain-specific signals, raising alarms against certain viral proteins but leaving the immune system to perform the actual clearance. This theory challenges the prevailing narrative that vaccines “save lives” by “preventing infection”, reframing them as tools that accelerate recognition rather than fighters that prevent or/and eliminate viruses.
The HVBI Theory also critiques the pharmaceutical industry’s framing of vaccines as preventive shields, pointing out that such messaging obscures the immune system’s decisive role. It emphasizes that vaccines cannot compensate for weak immunity, cannot address viral diversity, and cannot prevent persistence in immunocompromised individuals. By situating vaccines as biological impossibilities in terms of prevention, the theory calls for a more precise scientific narrative that acknowledges their limitations and contextualizes their role within immune dynamics.
(2) The Deliberate Discrediting Of HPV Screening And Treatment By Vaccine Lobby Post‑2006
The analysis of discrediting of screening and treatment highlights a troubling trend: after the introduction of HPV vaccines, emphasis on screening and treatment programs diminished significantly. Screening, which is critical for detecting persistent infections and preventing progression to cancer, was sidelined in favor of vaccine promotion. This shift created a dangerous gap, particularly for immunocompromised individuals and those infected with non‑covered strains.
The disappearance of screening and treatment programs post‑2006 from healthcare policies and discussions is framed as a systemic failure driven by pharmaceutical influence. By prioritizing vaccine narratives over screening and treatment, public health systems risked undermining the very mechanisms that protect individuals when clearance fails. The analysis argues that screening and treatment remains indispensable, as vaccines cannot prevent infection or guarantee clearance. The sidelining of screening and treatment is therefore not only scientifically unjustified but also ethically problematic, as it deprives populations of proven protective measures in favor of unproven preventive claims.
(3) HPV‑16 And HPV‑18: Immune System Dynamics, Vaccination, And Population-Level Outcomes
The discussion on immune system dynamics reinforces the centrality of the immune system in HPV clearance. It demonstrates that more than 95% of infections are naturally resolved within one to two years, with persistence and progression to cancer occurring only in rare cases of immune weakness. Vaccines, while useful in raising alarms, do not alter these timelines. They cannot prevent persistence in immunocompromised individuals, nor can they address infections from non‑covered strains.
At the population level, vaccines are credited with reducing cervical cancer incidence, but this attribution is misleading. The analysis argues that clearance is immune-driven, and vaccines merely accelerate recognition of certain strains. Messaging that credits vaccines with “saving lives” obscures the immune system’s decisive role and risks overstating vaccine efficacy. The article calls for a reframing of public health narratives to acknowledge vaccines as alarms, while situating clearance and protection within the broader context of immune strength and screening programs.
Discussion
The biological truth is nuanced: HPV vaccines are not shields that prevent infection, but alarms that accelerate recognition of very limited number of strains. They provide the immune system with a “wanted poster” of the intruder, enabling faster recognition but not altering the fight itself. The immune system remains the decisive actor: strong immunity clears infections quickly, while weak immunity allows persistence despite vaccination. This explains why persistence and cancers still occur in immunocompromised individuals despite HPV vaccination.
A critical issue highlighted in the HVBI Theory is the misattribution of credit in public health narratives. Natural immunity clears approximately 95% of HPV infections, including HPV‑16 and HPV‑18. The remaining infections are managed collectively through weaker immune responses, screening programs, and medical treatment. Yet, since the introduction of HPV vaccines in 2006, the dominant narrative has shifted to claim that every life saved is due to vaccination. This erases the contributions of natural immunity, screening, and treatment, and creates a distorted picture of vaccine efficacy. By appropriating credit, vaccines are portrayed as the sole saviors, while the immune system and medical interventions are sidelined. This narrative not only inflates vaccine impact but also undermines trust in scientific communication by failing to acknowledge the multifactorial nature of outcomes.
The implications of this misattribution are profound. Screening programs remain indispensable for detecting persistent infections and preventing progression to cancer, especially in immunocompromised individuals or those infected with non‑covered strains. Treatment interventions continue to play a vital role in managing cases where clearance fails. By claiming that vaccines alone are responsible for lives saved post‑2006, public health messaging risks weakening support for screening and treatment infrastructure, which are essential complements to immune clearance. A balanced narrative must recognize that vaccines are alarms, not shields, and that outcomes are achieved through the combined efforts of immunity, screening, and treatment.
Conclusion
HPV‑16 and HPV‑18 infections are overwhelmingly cleared by the immune system, not vaccines. Vaccines do not prevent infections; they serve as alarms that expose stealth oncogenic strains to immune recognition. The immune system clears infections, and screening plus treatment protect those for whom clearance fails. A more precise narrative would acknowledge vaccines as signals, while the immune system remains the final arbiter of outcome.
This distinction matters because it shapes how science communicates risk, efficacy, and credit. Misattributing all lives saved to vaccines since 2006 obscures the decisive role of natural immunity and the indispensable contributions of screening and treatment. The HVBI Theory calls for a reframing of public health narratives: HPV vaccines must be contextualized as just limited alarm tools for strains covered, within a broader immune and epidemiological framework, not glorified as independent saviors. Only then can we achieve a balanced, scientifically accurate understanding of HPV infections, HPV vaccines, and the immune system’s central role in outcomes.